Prevalence and identification of irregular erythrocyte antibodies in voluntary blood donors in the territory of Southeast Serbia

  • Milica Randjelović Blood Transfusion Institute of Niš, Niš, Serbia
  • Ana Veličković Blood Transfusion Institute of Niš, Niš, Serbia
  • Jelena Vojinović University Clinical Center of Niš, Pediatric Internal Diseases Clinic, Niš, Serbia; University of Niš, Faculty of Medicine, Niš, Serbia
  • Zoran Stanojković Blood Transfusion Institute of Niš, Niš, Serbia
Keywords: abo blood-group system;, antibodies;, blood donors;, serbia

Abstract


Background/Aim. The purpose of tests for transmittable diseases, as well as determining ABO group, Rh typing, and the presence of clinically significant erythrocyte antibodies, is to enable the appropriate selection of blood/blood components for transfusion, to prevent or minimize adverse effects of transfusion, and to identify donors whose units of blood/components are not suitable for transfusion. The aim of the study was to evaluate the presence of irregular erythrocyte antibodies as well as to determine the specificity and origin of these antibodies in voluntary donors. Methods. This prospective observational study, conducted from January until July 2023, included samples of voluntary blood donors (BDs) for antibody screening in the population of voluntary BDs in the territory of Southeast Serbia. A total of 23,082 samples from healthy BD were examined through this period. Results. The overall prevalence of irregular anti-erythrocyte antibodies was 0.1125%, with anti-K, anti-D, and anti-E being the most frequently identified alloantibodies. Out of a total of 26 donors with positive screening results, 11 (42.32%) had alloantibodies, and 15 (57.68%) had antibodies of undetermined specificity. A positive antibody test was observed more frequently in male donors, and the age range of 51 years and above accounted for the majority of positive cases. Conclusion. Immunohematological testing, including antibody screening in voluntary BDs, is important for safe blood transfusion and is of great clinical importance. Likewise, it reduces the risk of complications due to incompatible transfusions.

References

International Society of Blood Transfusion. Red cell Immunogenet-ics and Blood Group Terminology [Internet]. Amsterdam, the Netherlands: ISBT; 2023 [cited on 2024 Feb 22]. Available from: https://www.isbtweb.org/isbt-working-parties/rcibgt.html

Stites DP, Terr AI. Basic and clinical immunology. 7th ed. Norwalk, CT: Appleton and Lange; 1991. 817 p.

Mollison PL, Engelfriet CP, Contreras M. Blood Transfusion in Clinical Medicine. 9th ed. London: Blackwell Scientific; 1993. 1056 p.

Kovač M, Balint B, Bogdanović G. Basic and clinical transfu-sionology. Beograd: Medicinski fakultet Univerziteta u Beogradu, Akademska misao; 2020. 540 p. (Serbian)

Shaz BH. Antibody identification. In: Shaz BH, Hillyer CD, Zimring JC, Abshire TC, editors. Transfusion medicine and hemostasis: clinical and laboratory aspects. Amsterdam: Else-vier; 2009. p. 102–10.

Mohn JF, Lambert RM, Bowman HS, Brason FW. Experimental transfusion of donor plasma containing blood-group antibod-ies into incompatible normal human recipients. I. Absence of destruction of red-Kell and anti-M. Br J Haematol 1961; 7: 112–29.

Makroo RN, Rajput S, Agarwal S, Chowdhry M, Prakash B, Karna P. Prevalence of irregular red cell antibody in healthy blood donors attending a tertiary care hospital in North India. Asian J Transfus Sci 2018; 12(1): 17–20.

Council of Europe. Guide to the preparation, use and quality as-surance of blood components. Recommendation No. R(95)15. 21th ed [Internet]. France: Council of Europe; 2023 [cited on 2024 Feb 23]. Available from: https://www.edqm.eu/

en/blood-guide

Legal information system of the Republic of Serbia. Rulebook on the quality in the field of transfusion medicine. Official Gazette of the Republic Serbia, No 6/2019 [Internet]. Serbia: Official Gazette of the Republic Serbia; 2019 [cited on 2024 Feb 23]. Available from: https://www.pravno-informacioni-sistem.rs/SlGlasnikPortal/eli/rep/sgrs/ministarstva/pravilnik

/2019/6/9 (Serbian)

Legal information system of the Republic of Serbia. Law on transfusion medicine, Official Gazette of the Republic Serbia, No 40/2017 [Internet]. Serbia: Official Gazette of the Repub-lic Serbia; 2017 [cited on 2024 Feb 23]. Available from: https://www.pravno-informacionisitem.rs/SlGlasnikPortal/eli

/rep/sgrs/skupstina/zakon/2017/40/2. (Serbian)

Immucor. NEO Iris, Operator Manual. Norcross. GA: Immu-cor; 2017. Available from: https://www.scribd.com/document

/437855305/NEO-Iris-OperatorManual-JUNE2017

Diagnostic Grifols. Erytra, Instructions for Use. Barcelona, Spain: Grifols; 2016.

Brecher ME. Technical manual. American Association of Blood Banks. 14th ed. Bethesda: Maryland; 2002. p. 315–97.

Kaur D, Bains L, Kandwal M, Parmar I. Erythrocyte alloimmun-ization and autoimmunization among blood donors and recip-ients visiting a tertiary care hospital. J Clin Diagn Res 2017; 11(3): EC12–5.

Promwong C, Siammai S, Hassarin S, Buakaew J, Yeela T, Soisangwan P, et al. Frequencies and specificities of red cell al-loantibodies in the Southern Thai population. Asian J Transfus Sci 2013; 7(1): 16–20.

Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, et al. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Eval-uation Study-III (REDS-III). Transfusion 2019; 59(1): 217–25.

Keokhamphoui C, Urwijitaroon Y, Kongphaly D, Thammavong T. Red cell alloantibodies in Lao blood donors. Southeast Asian J Trop Med Public Health 2014; 45(1): 194–7.

Faramawy MSM, Hashem AEA, Mostafa GMH. Red blood cell alloantibodies in healthy Egyptian blood donors. Egypt J Hosp Med 2018; 72(7): 4913–8.

Pahuja S, Kushwaha S, Sethi N, Pujani M, Jain M. Screening of blood donors for erythrocyte alloantibodies. Hematology 2012; 17(5): 302–5.

Garg N, Sharma T, Singh B. Prevalence of irregular red blood cell antibodies among healthy blood donors in Delhi popula-tion. Transfus Apher Sci 2014; 50(3): 415–7.

Giblett ER. Blood group alloantibodies: an assessment of some laboratory practices. Transfusion 1977; 17(4): 299–308.

Ameen R, Al-Eyaadi O, Al-Shemmari S, Chowdhury R, Al-Bashir A. Frequency of red blood cell alloantibody in Kuwaiti popu-lation. Med Princ Pract 2005; 14(5): 230–4.

Winters JL, Pineda AA, Gorden LD, Bryant SC, Melton LJ 3rd, Vamvakas EC, et al. RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota. Transfusion 2001; 41(11): 1413–20.

Lee S, Zambas ED, Marsh WL, Redman CM. The human Kell blood group gene maps to chromosome 7q33 and its expres-sion is restricted to erythroid cells. Blood 1993; 81(10): 2804–9.

Marsh WL, Oyen R, Alicea E, Linter M, Horton S. Autoimmune hemolytic anemia and the Kell blood groups. Am J Hematol 1979; 7(2): 155–62.

Vaughan JI, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IA. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 1998; 338(12): 798–803.

Natukunda B, Schonewille H, van de Watering L, Brand A. Preva-lence and specificities of red blood cell alloantibodies in trans-fused Ugandans with different diseases. Vox Sang 2010; 98(2): 167–71.

Reyhaneh K, Ahmad G, Gharib K, Vida V, Raheleh K, Mehdi TN. Frequency & specificity of RBC alloantibodies in patients due for surgery in Iran. Indian J Med Res 2013; 138(2): 252–6.

Jovanović Srzentić S, Veljković DK. Immunobiological and clinical significance of blood groups. Beograd: Intra.Net Communica-tion; 2009. (Serbian)

Nathani KJ, Patel J, Modi P, Pandya A, Wadhwani S, Jarag M. Prevalence of red cell alloantibodies & autoantibodies in pa-tient & donor attending a tertiary care hospital in South Guja-rat. Int J Contemp Med Res 2021; 8(3): C1–5.

Daniels G. Human Blood Groups. 3rd ed. Oxford: Wiley Blackwell; 2013 p. 560.

Fung MK, Grossman BJ, Hillyer CD, Westhoff CM. ABO, H and Lewis blood groups and structurally related antigens, Rh sys-tem and other blood group system. In: Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, editors. Technical manual. 18th ed. Bethesda, Maryland: American Association of Blood Banks; 2014. p. 304–51.

Al-Joudi F, Ali AB, Ramli MB, Ahmed S, Ismail M. Prevalence and specificities of red cell alloantibodies among blood recipi-ents in the Malaysian state of Kelantan. Asian J Transfus Sci 2011; 5(1): 42–5.

Thakral B, Saluja K, Sharma RR, Marwaha N. Red cell alloim-munization in a transfused patient population: A study from a tertiary care hospital in north India. Hematology 2008; 13(5): 313–8.

Zaman S, Chaurasia R, Chatterjee K, Thapliyal RM. Prevalence and specificity of RBC alloantibodies in Indian patients at-tending a tertiary care hospital. Adv Hematol 2014; 2014: 749218.

Daniels G. Human Blood Groups. 1st ed. Oxford, UK: Blackwell Scientific; 1995.

Matson GA, Swanson J, Tobin JD. Severe hemolytic disease of the newborn caused by anti-Jka. Vox Sang 1959; 4(2): 144–7.

Combs MR. Lewis blood group system re-view. Immunohematology 2009; 25(3): 112–8.

Vojvodić S. Distribution of the ABO, Rh, MNSs, Kell and Duffy blood group antigens in the population of Vojvodina. Med Pregl 2003; 56(3–4): 173–7. (Serbian)

Published
2024/05/31
Section
Original Paper